- Nov 10, 2016The Medicines Patent Pool Announces First World Health Organization Prequalification Submissions for Generic DolutegravirCipla and Mylan are the first companies to apply for WHO’s prequalification of dolutegravir
- Nov 9, 2016
- Nov 8, 2016Potential to be First Submission of a Proposed Biosimilar Trastuzumab in the U.S.
- Nov 2, 2016Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)-- Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio --
- Oct 20, 2016Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Revefenacin Meets Primary Efficacy Endpoint and is Shown to be Well-Tolerated in Both Studies; Twelve-Month Safety Trial Ongoing and Targeted for Completion in 2017
- Oct 7, 2016Mylan updates full year 2016 earnings guidance